Evaluation of Efficacy and Safety of Highly Purified Urofollitropin in Chinese Females Undergoing an Assisted Reproductive Technology (ART) Program

NCT ID: NCT01922193

Last Updated: 2015-06-16

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 263 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-10-31
• Study Completion Date: 2015-04-30

Brief Summary

Evaluate the efficacy and safety of of Highly Purified Urofollitropin for Injection Compared to Recombinant Human Follitropin Alfa for Injection in Chinese Females Undergoing an Assisted Reproductive Technology (ART) Program.

Conditions

Infertility

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

Test Group

Group Type: EXPERIMENTAL

Highly Purified Urofollitropin

Intervention Type: DRUG

for injection

Control Group

Group Type: ACTIVE_COMPARATOR

Recombinant Human Follitropin Alfa

Intervention Type: DRUG

for injection

Interventions

Highly Purified Urofollitropin

for injection

Intervention Type: DRUG

Recombinant Human Follitropin Alfa

for injection

Intervention Type: DRUG

Other Intervention Names

Bravelle®; Gonal-F®

Eligibility Criteria

Inclusion Criteria

• Signed informed consent form, prior to screening evaluations
• In good physical and mental health
• Chinese Females between the ages of 20-39 years.
• Body mass index (BMI) is ≥ 18.5 and < 28 kg/m2
• Female diagnosed for at least one year (i.e., before screening) with tubal infertility, unexplained infertility, male factor infertility
• Regular menstrual cycles of 24-35 days (both inclusive), presumed to be ovulatory
• Documented evidence of at least one of the following within ninety (90) days prior to down regulation treatment:

• mid-luteal phase serum progesterone level > 5ng/mL, or
• late luteal phase endometrial biopsy with < 3 days lag, or
• biphasic basal body temperature chart, or
• mid-cycle urinary LH (Luteinizing hormone)surge
• Early follicular phase (day 2-3), serum levels of FSH within limits (1-12IU/L)(results obtained within 90 days prior to down regulation treatment)
• LH, PRL (prolactin), E2 (Estradiol), P (progesterone), total testosterone levels within normal range for the clinical laboratory or considered not clinically significant by the investigator (results obtained within 90 days prior to down regulation treatment)
• TSH (thyrotropin) levels within normal limits for the clinical laboratory or considered not clinically significant by the investigator, or secondary to exogenous thyroid medication (results obtained within 90 days prior to down regulation treatment)
• Negative serum Human Immunodeficiency Virus (HIV) antibody, and TPPA (Treponema Pallidum antibodies)/ RPR (Rapid Plasma Reagin) tests (results obtained within 90 days prior to down regulation treatment)
• Early follicular phase total antral follicle (diameter 2-10 mm) count ≥ 6 and ≤ 25 for both ovaries combined (results obtained within 3 months prior to down regulation treatment)
• Transvaginal ultrasound documenting presence and adequate visualisation of both ovaries, uterus and adnexa without evidence of significant abnormality (e.g.no endometrioma greater than 3 cm, no ovarian cysts > 35 mm or enlarged ovaries which would contraindicate the use of down regulation treatment, no hydrosalpinx) within ninety (90) days prior to down regulation treatment
• Hysterosalpingography, hysteroscopy, saline infusion sonography or transvaginal ultrasound documenting a uterus consistent with expected normal function (e.g.no evidence of clinically interfering uterine fibroids defined as submucous or intramural fibroids larger than 3 cm in diameter, no polyps and no congenital structural abnormalities which are incompatible with pregnancy) within 1 year prior to down regulation treatment. This also includes women who have been diagnosed with any of the above medical conditions but have had them surgically corrected.
• A minimum of one cycle without treatment with fertility modifiers (e.g., oral contraceptives) during the last menstrual cycle before down regulation treatment
• Willing to accept a maximum of two embryos transferred in the fresh cycle
• Willing to use an adequate barrier method of contraception or refrain from intercourse from 2 weeks before start of down regulation and throughout the down regulation period

Exclusion Criteria

• Any pregnancy within last three (3) months prior to screening
• Known past or current thrombophlebitis or thromboembolism including venous thrombosis disease and active or recent arterial thrombosis disease
• Three or more controlled ovarian stimulation cycles for IVF/ICSI (In vitro fertilization/Intracytoplasmic sperm injection) prior to screening
• Previous IVF or ART failure related to a sperm/fertilization problem which resulted in unsuccessful fertilization and no related medical conditions improved
• Known history of poor ovarian response in a previous controlled ovarian stimulation cycle for IVF/ICSI
• Known history of excessive ovarian response in a previous controlled ovarian stimulation cycle for IVF/ICSI
• Known severe OHSS (Ovarian hyperstimulating syndrome) in a previous controlled ovarian stimulation cycle.
• Known history of polycystic ovary disease (PCOD) associated with anovulation
• Known endometriosis
• Known abnormal results of cervical examination of clinical significance obtained within 1 year prior to screening
• Abnormal vaginal bleeding of undetermined origin
• Known tumors of the ovary, breast, uterus, adrenal gland, pituitary or hypothalamus
• Known current active pelvic inflammatory disease
• Known history of recurrent miscarriage
• Known malformations of the sexual organs incompatible with pregnancy
• According to the judgment of the investigator, abnormal laboratory value of renal or hepatic function is clinically significant
• Known current (3 months prior to screening) or past (1 year prior to screening) abuse of alcohol or drugs, and/or current or past smoking habit of more than 10 cigarettes per day
• Any known endocrine or metabolic abnormalities (pituitary, adrenal, pancreas, liver or kidney) which can compromise participation in the trial with the exception of controlled thyroid function disease
• Known history of chemotherapy (except for gestational conditions) or radiotherapy
• According to the judgment of the investigator, abnormal laboratory value is clinically relevant
• Use of any non-registered investigational drugs during 3 months before screening or previous participation in the study

• Minimum Eligible Age: 20 Years
• Maximum Eligible Age: 39 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Ferring Pharmaceuticals

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Clinical Development Support

Role: STUDY_DIRECTOR

Ferring Pharmaceuticals

Locations

Chinese PLA General Hospital

Beijing, Beijing Municipality, China

Peking Union Medical College Hospital

Beijing, Beijing Municipality, China

Peking University First Hospital

Beijing, Beijing Municipality, China

Peking University People's Hospital

Beijing, Beijing Municipality, China

Sun Yat-sen Memorial Hospital Sun Yat-sen University

Guangzhou, Guangdong, China

The third Affiliated Hospital of Guangzhou Medical University

Guangzhou, Guangdong, China

Tongji Hospital Tongji Medical College of HUST Tongji Medical College Huazhong University of Science & Technology

Wuhan, Hubei, China

The First Affiliated Hospital with Nanjing Medical University

Nanjing, Jiangsu, China

ShengJing Hospital of China Medical University

Shenyang, Liaoning, China

Sichuan Provincial People's Hospital

Chengdu, Sichuan, China

Tianjin Medical University General Hospital

Tianjin, Tianjin Municipality, China

Countries

China

Other Identifiers

000089

Identifier Type: -

Identifier Source: org_study_id